(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|
Turnover | 15.19%7.6B | -6.14%13.75B | 64.19%6.59B | 594.49%14.65B | --4.02B | 132.54%2.11B | 288.87%906.99M | --233.24M |
Operating income | 15.19%7.6B | -6.14%13.75B | 64.19%6.59B | 594.49%14.65B | 4.02B | 132.54%2.11B | 288.87%906.99M | 233.24M |
Cost of sales | -15.75%-7.32B | 0.77%-13.46B | -52.18%-6.33B | -457.08%-13.56B | ---4.16B | -205.82%-2.43B | -222.88%-795.89M | ---246.5M |
Operating expenses | -15.75%-7.32B | 0.77%-13.46B | -52.18%-6.33B | -457.08%-13.56B | -4.16B | -205.82%-2.43B | -222.88%-795.89M | -246.5M |
Gross profit | 1.92%272.37M | -73.04%293.35M | 289.14%267.23M | 434.98%1.09B | -141.29M | -392.43%-324.88M | 937.97%111.1M | -13.26M |
Selling expenses | -42.21%-224.29M | -18.15%-379.03M | -59.47%-157.72M | -343.42%-320.8M | ---98.9M | -112.56%-72.35M | -192.10%-34.04M | ---11.65M |
Administrative expenses | -25.49%-300.74M | -62.88%-564.83M | -57.92%-239.66M | -115.92%-346.79M | ---151.76M | -372.29%-160.61M | -76.73%-34.01M | ---19.24M |
Research and development expenses | 19.59%-406.28M | -29.13%-991.31M | -96.49%-505.25M | -212.63%-767.69M | ---257.14M | -237.69%-245.56M | -53.23%-72.72M | ---47.46M |
Impairment and provision | 58.39%-103.65M | -267.32%-297.71M | -11,316.22%-249.1M | -5,013.56%-81.05M | ---2.18M | 18.76%-1.59M | -1,812.75%-1.95M | ---102K |
-Other impairment is provision | 58.39%-103.65M | -267.32%-297.71M | -11,316.22%-249.1M | -5,013.56%-81.05M | ---2.18M | 18.76%-1.59M | -1,812.75%-1.95M | ---102K |
Operating interest expense | ---- | ---- | ---- | ---- | ---78.18M | -43.40%-32.66M | ---22.78M | ---- |
Special items of operating profit | 248.74%279.6M | 53.31%257.17M | 234.39%80.17M | 401.76%167.74M | --23.98M | 2,917.24%33.43M | -81.02%1.11M | --5.84M |
Operating profit | 39.95%-482.99M | -546.35%-1.68B | -14.01%-804.31M | 67.63%-260.29M | -705.47M | -1,409.43%-804.21M | 37.96%-53.28M | -85.87M |
Financing cost | -50.66%-170.41M | -35.95%-256.85M | ---113.11M | ---188.93M | ---- | ---- | ---- | ---26M |
Share of profits of associates | ---1.91M | ---595K | ---- | ---- | ---- | ---- | ---- | ---- |
Share of profit from joint venture company | -321.88%-2.87M | 34.03%-1.05M | ---681K | ---1.59M | ---- | ---- | ---- | ---- |
Earning before tax | 28.31%-658.18M | -330.54%-1.94B | -30.14%-918.11M | 43.95%-450.8M | -705.47M | -1,409.43%-804.21M | 52.38%-53.28M | -111.87M |
Tax | 98.03%-32K | -9,648.00%-2.44M | ---1.63M | ---25K | ---- | ---- | ---- | ---- |
After-tax profit from continuing operations | 28.43%-658.21M | -331.06%-1.94B | -30.37%-919.73M | 43.94%-450.82M | -705.47M | -1,409.43%-804.21M | 52.38%-53.28M | -111.87M |
Earning after tax | 28.43%-658.21M | -331.06%-1.94B | -30.37%-919.73M | 43.94%-450.82M | -705.47M | -1,409.43%-804.21M | 52.38%-53.28M | -111.87M |
Minority profit | -2.73%-215.24M | -387.58%-471.5M | -117.25%-209.52M | -11.17%-96.7M | ---96.44M | -599.44%-86.98M | ---12.44M | ---- |
Profit attributable to shareholders | 37.63%-442.97M | -315.62%-1.47B | -16.61%-710.22M | 50.63%-354.12M | -609.03M | -1,656.06%-717.23M | 63.49%-40.84M | -111.87M |
Basic earnings per share | 42.42%-0.19 | -240.00%-0.68 | 17.50%-0.33 | 81.48%-0.2 | -0.4 | -671.43%-1.08 | 62.16%-0.14 | -0.37 |
Diluted earnings per share | 42.42%-0.19 | -240.00%-0.68 | 17.50%-0.33 | 81.48%-0.2 | -0.4 | -671.43%-1.08 | 62.16%-0.14 | -0.37 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data